Show simple item record Kovács, Gábor Kiss C, 2018-07-20T08:58:08Z 2018-07-20T08:58:08Z 2017
dc.identifier.citation pagination=1891-1896; journalVolume=158; journalIssueNumber=48; journalTitle=ORVOSI HETILAP;
dc.identifier.uri doi:10.1556/650.2017.30934
dc.description.abstract Immune thrombocitopenia in children is a very variable disease. International recommendations give therapeutic possibilities without strong protocols. In 2011, a therapeutic algorithm was published based on Hungarian practice. Recently, new innovative drugs have been available even in Hungary, so there is a need for modification of the therapeutic protocols. In this summary we give an overview about the current up-to-date management. In infancy and in childhood, high-dose immunglobulin treatment is recommended henceforward. In older children an alternative can be steroid therapy (pulses or long-term low-dose treatment). In resistant cases, a new thrombopoetin receptor stimulant, eltrombopag can be administered. This drug is registered in Hungary, and can very effectively influence the prognosis. Splenectomy is very rare nowadays in children. Immune thrombocytopenia is an unpredictable disease. Cure rate is about 70-80% of the cases, but management of the patients needs special care and specialist. Orv Hetil. 2017; 158(48): 1891-1896.
dc.relation.ispartof urn:issn:0030-6002
dc.title Újdonságok a gyermekkori immunthrombocytopenia kezelésében - 2017
dc.type Journal Article 2018-07-16T12:10:32Z
dc.language.rfc3066 hu
dc.identifier.mtmt 3333975
dc.identifier.wos WOS:000416257600001
dc.identifier.pubmed 29172661

Files in this item



This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account